News

PerkinElmer to Acquire Oxford Immunotec Global PLC

Details

PerkinElmer and Oxford Immunotec Global PLC are pleased to announce they have reached an agreement on terms under which PerkinElmer will acquire Oxford Immunotec. 

CARISMA Therapeutics Completes Series B Funding for $47 Million to Advance Development of Novel CAR-Macrophage Immunotherapies

Details

CARISMA Therapeutics announced today that it has completed its Series B equity financing providing for gross proceeds of $47 million, bringing CARISMA’s total capital raised to nearly $109 million. 

Adrenomed Supervisory Board appoints Dr. Wolfgang Baiker as CEO

Details

Adrenomed AG, the vascular integrity company, announced today that its Supervisory Board has appointed Dr. Wolfgang Baiker as Chief Executive Officer (CEO) effective January 1, 2021. 

  1. MinervaX raises upsized EUR 47.4M (USD 57M) Series B to advance its novel Group B Streptococcus vaccine through mid-stage clinical trials
  2. Immatics Presents Phase I Data from ACTolog® Multi-Target Pilot Study IMA101 at the 35th Annual SITC Conference
  3. Koa Health secures over €14m initial funding and spins out of Telefónica’s moonshot factory
  4. Digital therapeutics leader Sidekick raises $20M in Series A funding round led by Wellington and Asabys
© Wellington Partners, 2021.